Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Olivero

Showing results (81-90 of 81) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 81 results.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Pageof 9

Showing results (81-90 of 81) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 81 results.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Pageof 9